HALO & HALOVISC

HALO & HALOVISC

ANTI-INFLAMMATORY, ANTI-ARTHRITIC & CHONDROPROTECTIVE AGENT FOR USE IN HORSES

COMPOSITION
HALO INTRA-VENOUS
6mL SODIUM HYALURONATE 20mg/mL (Medium Molecular Weight 0.45 x 10 Da)

HALOVISC INTRA-ARTICULAR
2mL SODIUM HYALURONATE 10mg/mL (High Molecular Weight 1.35 x 10 Da)


ACTIONS
Sodium hyaluronate, the sodium salt of hyaluronic acid (HA), is a non-sulphate glycosaminoglycan (GAG) which is present in many body tissues including connective tissue and skin and is synovial (joint) fluid in very high concentrations. HA provides visco-electic properties to joint fluid and functions as a lubricant.

In joint disease, inflammation leads to the accumulation of inflammatory cells and degradative enzymes in the joint fluid which break down HA. The loss of HA results in lowered viscosity of the joint fluid and further influx of inflammatory cells, leading to additional cartilage damage and joint disease. Supplementation of sodium hyaluronate to the joint works to replace HA lost during joint disease and thereby restores lubrication of the joint, reduces inflammatory infiltrates and minimises ongoing damage.


INDICATIONS
To aid in the management of non-infectious inflammatory joint disease in horse.


DOSAGE AND ADMINISTRATION
Intra-Venous Use:
HALO INTRA-VENOUS contains medium molecular weight Sodium Hyaluronate with lower viscosity allowing intra-venous injection.

DOSAGE: Administer 6mL HALO INTRA-VENOUS (1 vial) by strict aseptic technique. Treatment may be repeated at 3 - 9 day (optimal 7 days) intervals for a total of 5 - 7 treatments.

Intra-Articular Use:
HAVOLISC INTRA-ARTICULAR contains high molecular weight Sodium Hyaluronate with very high viscosity requiring direct injection into the joint, tendon sheath or lesion.

DOSAGE: Administer 2mL HALOVISC INTRA-ARTICULAR (1 vial) by strict aseptic technique. Treatment may be repeated at 3 - 7 day (optimal 5 days) intervals for a total of 3 treatments.

Where massive cascularisation of the synovia exist, intra-venous administration may promote wider delivery of the exogenous sodium hyaluronate to synoviocytes. Intra-venous administration may promote wider delivery of the exogenous sodium hyaluronate to synoviocytes. Intra-venous administration may also be preferable for animals with chronic and/or multiple problems.

Studies have demonstrated the short-term and long-term effectiveness of Halo and Haloviac to be equivalent.

Combination of sodium hyaluronate with corticosteroids for the treatment of joint disease may produce a more rapid response than either product administered alone. In addition, sodium hyaluronate may reduce the potential deleterious effects of corticosteroids on joint structures.


PRESENTATION
HALO INTRA-VENOUS pack contains: 6 vials of 6mL Sodium Hyaluronate 10mg/mL (Medium Molecular Weight 0.45 x 10 Da)

HALOVISC INTRA-ARTICULAR pack contains: 6 vials of 2mL Sodium Hyaluronate 10mg/mL (High Molecular Weight 1.35 x 10 Da)


STORAGE
Store below 25 celcius (air conditioning).